A Phase 4 interventional study of Trumenba in Meningococcal Vaccine, sponsored by Pfizer. Completed at 14 sites in 3 countries. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 13th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2021, is one of 3 in phase 4, and was the 16th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Brazil, India and 4 more countries
Ages 12+
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 10 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 5 · Phase 3 11 · Phase 4 3
First in 2014; this study’s year is marked. 5 started in 2021.
This study's enrollment of 53 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 52 across the 27 interventional studies, 216 across the 3 observational. Of the 28 that completed or were terminated, 19 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally assessing antibody production in asplenic and complement-deficient individuals ≥10 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bivalent recombinant lipoprotein 2086 vaccine
Biological: Trumenba
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
Bivalent recombinant lipoprotein 2086 vaccine
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer => Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains at Baseline
Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) more than or equal to (=\>)1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 are reported. Evaluable immunogenicity population (EIP) included all participants who were eligible through 1 month after Vaccination 2, received the study vaccination at Visit 1 and Visit 3 as planned, had blood drawn for assay testing within the required time frames at Visit 1 (before Vaccination 1) and 1 month after Vaccination 2 (28-42 days after Visit 3), had at least 1 valid and determinate assay result 1 month after Vaccination 2, received no prohibited vaccines or medications through Visit 4, and had no major protocol deviations through Visit 4.
Time frame: Baseline (Before Vaccination 1 on Day 1/Month 0)
Percentage of Participants With hSBA Titer => LLOQ for Each of the 4 Primary MnB Test Strains at 1 Month After Vaccination 2
Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) =\>1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 were reported.
Time frame: 1 Month after Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 1
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 2
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 1
Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree Celsius (C), 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hours \[hrs\]), moderate (\>2 times in 24 hrs) and severe (required intravenous \[IV\] hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).
Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 2
Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree C, 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hrs), moderate (\>2 times in 24 hrs) and severe (required IV hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).
Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1
Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2
Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants Reporting Adverse Events (AEs) During 30 Days After Vaccination 1
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Percentage of Participants Reporting AEs During 30 Days After Vaccination 2
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants Reporting AEs During 30 Days After Any Vaccination
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
Time frame: 30 Days after any Vaccination
Percentage of Participants Reporting AEs During the Vaccination Phase
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
Time frame: Vaccination Phase: From Vaccination 1 through one Month after Vaccination 2 (approximately 7 Months)
Percentage of Participants Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Percentage of Participants Reporting SAEs During 30 Days After Vaccination 2
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants Reporting SAEs During 30 Days After Any Vaccination
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
Time frame: 30 Days after any Vaccination
Percentage of Participants Reporting SAEs During the Vaccination Phase
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Percentage of Participants Reporting SAEs During the Follow-up Phase
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
Time frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
Percentage of Participants Reporting SAEs During the Entire Study
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
Percentage of Participants Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Percentage of Participants Reporting MAEs During 30 Days After Vaccination 2
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants Reporting MAEs During 30 Days After Any Vaccination
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 Days after any Vaccination
Percentage of Participants Reporting MAEs During the Vaccination Phase
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Percentage of Participants Reporting MAEs During the Follow-up Phase
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
Percentage of Participants Reporting MAEs During the Entire Study
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
Percentage of Participants Reporting Immediate AEs After Vaccination 1
Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.
Time frame: 30 Minutes post Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Percentage of Participants Reporting Immediate AEs After Vaccination 2
Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.
Time frame: 30 Minutes post Vaccination 2 (Vaccination 2 at Month 6)
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Percentage of Participants With NDCMC During the Follow-up Phase
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
Percentage of Participants With NDCMC During the Entire Study
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
Mean Number of Days Participants Missed School or Work Because of AEs During the Vaccination Phase
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
A total of 53 immunocompromised participants greater than or equal to (\>=) 10 years of age with asplenia (anatomic or functional) or complement deficiency were enrolled and received Trumenba on a 2-dose, 0- and 6-month schedule in the Study B1971060 \[NCT04893811\].
| Milestone | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Started | 53 | 51 |
| Vaccination 1 | 53 | 51 |
| Vaccination 2 | 47 | 47 |
| Completed | 47 | 47 |
| Not completed | 6 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Other | 0 | 1 |
| Withdrew: No longer met eligibility criteria | 0 | 1 |
| Milestone | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Started | 47 | 47 |
| Follow-up safety set | 44 | 48 |
| Completed | 47 | 46 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) more than or equal to (=\>)1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 are reported. Evaluable immunogenicity population (EIP) included all participants who were eligible through 1 month after Vaccination 2, received the study vaccination at Visit 1 and Visit 3 as planned, had blood drawn for assay testing within the required time frames at Visit 1 (before Vaccination 1) and 1 month after Vaccination 2 (28-42 days after Visit 3), had at least 1 valid and determinate assay result 1 month after Vaccination 2, received no prohibited vaccines or medications through Visit 4, and had no major protocol deviations through Visit 4.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| PMB80 (A22) | 32.6 (19.1 to 48.5) | 31.0 (17.6 to 47.1) |
| PMB2001 (A56) | 25.6 (13.5 to 41.2) | 23.3 (11.8 to 38.6) |
| PMB2948 (B24) | 2.4 (0.1 to 12.6) | 23.3 (11.8 to 38.6) |
| PMB2707 (B44) | 9.3 (2.6 to 22.1) | 11.4 (3.8 to 24.6) |
Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) =\>1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 were reported.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| PMB80 (A22) | 75.0 (59.7 to 86.8) | 95.3 (84.2 to 99.4) |
| PMB2001 (A56) | 90.9 (78.3 to 97.5) | 100.0 (92.0 to 100.0) |
| PMB2948 (B24) | 70.5 (54.8 to 83.2) | 81.8 (67.3 to 91.8) |
| PMB2707 (B44) | 79.1 (64.0 to 90.0) | 92.9 (80.5 to 98.5) |
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Redness: Any | 18.9 (9.4 to 32.0) | 11.8 (4.4 to 23.9) |
| Redness: Mild | 5.7 (1.2 to 15.7) | 5.9 (1.2 to 16.2) |
| Redness: Moderate | 9.4 (3.1 to 20.7) | 3.9 (0.5 to 13.5) |
| Redness: Severe | 3.8 (0.5 to 13.0) | 2.0 (0.0 to 10.4) |
| Swelling: Any | 22.6 (12.3 to 36.2) | 11.8 (4.4 to 23.9) |
| Swelling: Mild | 7.5 (2.1 to 18.2) | 7.8 (2.2 to 18.9) |
| Swelling: Moderate | 15.1 (6.7 to 27.6) | 3.9 (0.5 to 13.5) |
| Swelling: Severe | 0 (0.0 to 6.7) | 0 (0.0 to 7.0) |
| Pain at injection site: Any | 86.8 (74.7 to 94.5) | 80.4 (66.9 to 90.2) |
| Pain at injection site: Mild | 41.5 (28.1 to 55.9) | 47.1 (32.9 to 61.5) |
| Pain at injection site: Moderate | 32.1 (19.9 to 46.3) | 33.3 (20.8 to 47.9) |
| Pain at injection site: Severe | 13.2 (5.5 to 25.3) | 0 (0.0 to 7.0) |
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Redness: Any | 20.0 (9.6 to 34.6) | 7.0 (1.5 to 19.1) |
| Redness: Mild | 6.7 (1.4 to 18.3) | 2.3 (0.1 to 12.3) |
| Redness: Moderate | 11.1 (3.7 to 24.1) | 4.7 (0.6 to 15.8) |
| Redness: Severe | 2.2 (0.1 to 11.8) | 0 (0.0 to 8.2) |
| Swelling: Any | 26.7 (14.6 to 41.9) | 4.7 (0.6 to 15.8) |
| Swelling: Mild | 13.3 (5.1 to 26.8) | 0 (0.0 to 8.2) |
| Swelling: Moderate | 13.3 (5.1 to 26.8) | 4.7 (0.6 to 15.8) |
| Swelling: Severe | 0 (0.0 to 7.9) | 0 (0.0 to 8.2) |
| Pain at injection site: Any | 93.3 (81.7 to 98.6) | 60.5 (44.4 to 75.0) |
| Pain at injection site: Mild | 44.4 (29.6 to 60.0) | 30.2 (17.2 to 46.1) |
| Pain at injection site: Moderate | 35.6 (21.9 to 51.2) | 27.9 (15.3 to 43.7) |
| Pain at injection site: Severe | 13.3 (5.1 to 26.8) | 2.3 (0.1 to 12.3) |
Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree Celsius (C), 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hours \[hrs\]), moderate (\>2 times in 24 hrs) and severe (required intravenous \[IV\] hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Fever: =>38.0 degree C | 3.8 (0.5 to 13.0) | 2.0 (0.0 to 10.4) |
| Fever: 38.0 to 38.4 degree C | 1.9 (0.0 to 10.1) | 0 (0.0 to 7.0) |
| Fever: >38.4 to 38.9 degree C | 0 (0.0 to 6.7) | 2.0 (0.0 to 10.4) |
| Fever: >38.9 to 40.0 degree C | 1.9 (0.0 to 10.1) | 0 (0.0 to 7.0) |
| Fever: >40.0 degree C | 0 (0.0 to 6.7) | 0 (0.0 to 7.0) |
| Fatigue: Any | 54.7 (40.4 to 68.4) | 51.0 (36.6 to 65.2) |
| Fatigue: Mild | 26.4 (15.3 to 40.3) | 39.2 (25.8 to 53.9) |
| Fatigue: Moderate | 22.6 (12.3 to 36.2) | 11.8 (4.4 to 23.9) |
| Fatigue: Severe | 5.7 (1.2 to 15.7) | 0 (0.0 to 7.0) |
| Headache: Any | 41.5 (28.1 to 55.9) | 29.4 (17.5 to 43.8) |
| Headache: Mild | 18.9 (9.4 to 32.0) | 25.5 (14.3 to 39.6) |
| Headache: Moderate | 18.9 (9.4 to 32.0) | 2.0 (0.0 to 10.4) |
| Headache: Severe | 3.8 (0.5 to 13.0) | 2.0 (0.0 to 10.4) |
| Chills: Any | 15.1 (6.7 to 27.6) | 19.6 (9.8 to 33.1) |
| Chills: Mild | 11.3 (4.3 to 23.0) | 17.6 (8.4 to 30.9) |
| Chills: Moderate | 1.9 (0.0 to 10.1) | 2.0 (0.0 to 10.4) |
| Chills: Severe | 1.9 (0.0 to 10.1) | 0 (0.0 to 7.0) |
| Muscle Pain: Any | 26.4 (15.3 to 40.3) | 23.5 (12.8 to 37.5) |
| Muscle Pain: Mild | 15.1 (6.7 to 27.6) | 11.8 (4.4 to 23.9) |
| Muscle Pain: Moderate | 9.4 (3.1 to 20.7) | 9.8 (3.3 to 21.4) |
| Muscle Pain: Severe | 1.9 (0.0 to 10.1) | 2.0 (0.0 to 10.4) |
| Joint Pain: Any | 22.6 (12.3 to 36.2) | 19.6 (9.8 to 33.1) |
| Joint Pain: Mild | 9.4 (3.1 to 20.7) | 11.8 (4.4 to 23.9) |
| Joint Pain: Moderate | 9.4 (3.1 to 20.7) | 5.9 (1.2 to 16.2) |
| Joint Pain: Severe | 3.8 (0.5 to 13.0) | 2.0 (0.0 to 10.4) |
| Vomiting: Any | 1.9 (0.0 to 10.1) | 2.0 (0.0 to 10.4) |
| Vomiting: Mild | 1.9 (0.0 to 10.1) | 2.0 (0.0 to 10.4) |
| Vomiting: Moderate | 0 (0.0 to 6.7) | 0 (0.0 to 7.0) |
| Vomiting: Severe | 0 (0.0 to 6.7) | 0 (0.0 to 7.0) |
| Diarrhea: Any | 9.4 (3.1 to 20.7) | 11.8 (4.4 to 23.9) |
| Diarrhea: Mild | 9.4 (3.1 to 20.7) | 5.9 (1.2 to 16.2) |
| Diarrhea: Moderate | 0 (0.0 to 6.7) | 5.9 (1.2 to 16.2) |
| Diarrhea: Severe | 0 (0.0 to 6.7) | 0 (0.0 to 7.0) |
Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree C, 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hrs), moderate (\>2 times in 24 hrs) and severe (required IV hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Fever: =>38.0 degree C | 2.2 (0.1 to 11.8) | 2.3 (0.1 to 12.3) |
| Fever: 38.0 to 38.4 degree C | 2.2 (0.1 to 11.8) | 0 (0.0 to 8.2) |
| Fever: >38.4 to 38.9 degree C | 0 (0.0 to 7.9) | 2.3 (0.1 to 12.3) |
| Fever: >38.9 to 40.0 degree C | 0 (0.0 to 7.9) | 0 (0.0 to 8.2) |
| Fever: >40.0 degree C | 0 (0.0 to 7.9) | 0 (0.0 to 8.2) |
| Fatigue: Any | 53.3 (37.9 to 68.3) | 41.9 (27.0 to 57.9) |
| Fatigue: Mild | 24.4 (12.9 to 39.5) | 23.3 (11.8 to 38.6) |
| Fatigue: Moderate | 24.4 (12.9 to 39.5) | 14.0 (5.3 to 27.9) |
| Fatigue: Severe | 4.4 (0.5 to 15.1) | 4.7 (0.6 to 15.8) |
| Headache: Any | 35.6 (21.9 to 51.2) | 30.2 (17.2 to 46.1) |
| Headache: Mild | 6.7 (1.4 to 18.3) | 23.3 (11.8 to 38.6) |
| Headache: Moderate | 22.2 (11.2 to 37.1) | 7.0 (1.5 to 19.1) |
| Headache: Severe | 6.7 (1.4 to 18.3) | 0 (0.0 to 8.2) |
| Chills: Any | 8.9 (2.5 to 21.2) | 14.0 (5.3 to 27.9) |
| Chills: Mild | 4.4 (0.5 to 15.1) | 11.6 (3.9 to 25.1) |
| Chills: Moderate | 2.2 (0.1 to 11.8) | 2.3 (0.1 to 12.3) |
| Chills: Severe | 2.2 (0.1 to 11.8) | 0 (0.0 to 8.2) |
| Muscle Pain: Any | 13.3 (5.1 to 26.8) | 11.6 (3.9 to 25.1) |
| Muscle Pain: Mild | 4.4 (0.5 to 15.1) | 7.0 (1.5 to 19.1) |
| Muscle Pain: Moderate | 8.9 (2.5 to 21.2) | 2.3 (0.1 to 12.3) |
| Muscle Pain: Severe | 0 (0.0 to 7.9) | 2.3 (0.1 to 12.3) |
| Joint Pain: Any | 20.0 (9.6 to 34.6) | 16.3 (6.8 to 30.7) |
| Joint Pain: Mild | 6.7 (1.4 to 18.3) | 14.0 (5.3 to 27.9) |
| Joint Pain: Moderate | 11.1 (3.7 to 24.1) | 0 (0.0 to 8.2) |
| Joint Pain: Severe | 2.2 (0.1 to 11.8) | 2.3 (0.1 to 12.3) |
| Vomiting: Any | 2.2 (0.1 to 11.8) | 0 (0.0 to 8.2) |
| Vomiting: Mild | 2.2 (0.1 to 11.8) | 0 (0.0 to 8.2) |
| Vomiting: Moderate | 0 (0.0 to 7.9) | 0 (0.0 to 8.2) |
| Vomiting: Severe | 0 (0.0 to 7.9) | 0 (0.0 to 8.2) |
| Diarrhea: Any | 8.9 (2.5 to 21.2) | 4.7 (0.6 to 15.8) |
| Diarrhea: Mild | 6.7 (1.4 to 18.3) | 4.7 (0.6 to 15.8) |
| Diarrhea: Moderate | 2.2 (0.1 to 11.8) | 0 (0.0 to 8.2) |
| Diarrhea: Severe | 0 (0.0 to 7.9) | 0 (0.0 to 8.2) |
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1 | 34.0 (21.5 to 48.3) | 9.8 (3.3 to 21.4) |
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2 | 28.9 (16.4 to 44.3) | 7.0 (1.5 to 19.1) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting Adverse Events (AEs) During 30 Days After Vaccination 1 | 26.4 (15.3 to 40.3) | 9.8 (3.3 to 21.4) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting AEs During 30 Days After Vaccination 2 | 12.8 (4.8 to 25.7) | 12.8 (4.8 to 25.7) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting AEs During 30 Days After Any Vaccination | 34.0 (21.5 to 48.3) | 17.6 (8.4 to 30.9) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting AEs During the Vaccination Phase | 60.4 (46.0 to 73.5) | 41.2 (27.6 to 55.8) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1 | 9.4 (3.1 to 20.7) | 0 (0.0 to 7.0) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting SAEs During 30 Days After Vaccination 2 | 0 (0.0 to 7.5) | 0 (0.0 to 7.5) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting SAEs During 30 Days After Any Vaccination | 9.4 (3.1 to 20.7) | 0 (0.0 to 7.0) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting SAEs During the Vaccination Phase | 17.0 (8.1 to 29.8) | 0 (0.0 to 7.0) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting SAEs During the Follow-up Phase | 4.5 (0.6 to 15.5) | 2.1 (0.1 to 11.1) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting SAEs During the Entire Study | 18.9 (9.4 to 32.0) | 2.0 (0.0 to 10.4) |
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1 | 20.8 (10.8 to 34.1) | 5.9 (1.2 to 16.2) |
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting MAEs During 30 Days After Vaccination 2 | 12.8 (4.8 to 25.7) | 4.3 (0.5 to 14.5) |
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting MAEs During 30 Days After Any Vaccination | 30.2 (18.3 to 44.3) | 9.8 (3.3 to 21.4) |
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting MAEs During the Vaccination Phase | 54.7 (40.4 to 68.4) | 29.4 (17.5 to 43.8) |
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting MAEs During the Follow-up Phase | 15.9 (6.6 to 30.1) | 10.4 (3.5 to 22.7) |
MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting MAEs During the Entire Study | 60.4 (46.0 to 73.5) | 31.4 (19.1 to 45.9) |
Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting Immediate AEs After Vaccination 1 | 0 (0.0 to 6.7) | 2.0 (0.0 to 10.4) |
Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants Reporting Immediate AEs After Vaccination 2 | 0 (0.0 to 7.5) | 0 (0.0 to 7.5) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase | 1.9 (0.0 to 10.1) | 0 (0.0 to 7.0) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants With NDCMC During the Follow-up Phase | 0 (0.0 to 8.0) | 0 (0.0 to 7.4) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Percentage of Participants With NDCMC During the Entire Study | 1.9 (0.0 to 10.1) | 0 (0.0 to 7.0) |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Days | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Mean Number of Days Participants Missed School or Work Because of AEs During the Vaccination Phase | 12.7 ± 7.6 | 2.5 ± 2.3 |
Collected over Local reactions, systemic events within 7 days of each vaccination; SAEs and Non-SAEs: From Day 1 of vaccination up to 6 months after last study vaccination (approximately 12 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trumenba (B1971060) | 1/53 (1.9%) | 10/53 (18.9%) | 51/53 (96.2%) |
| Trumenba (B1971057, Historical Age- and Sex-Matched Control) | 0/51 (0%) | 1/51 (2%) | 49/51 (96.1%) |
| Event | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 4/53 | 0/51 |
| COVID-19Infections and infestations | 2/53 | 0/51 |
| PneumoniaInfections and infestations | 0/53 | 1/51 |
| Acute myocardial infarctionCardiac disorders | 1/53 | 0/51 |
| Cardiac arrestCardiac disorders | 1/53 | 0/51 |
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 1/53 | 0/51 |
| Pancreatitis chronicGastrointestinal disorders | 1/53 | 0/51 |
| Urinary tract infectionInfections and infestations | 1/53 | 0/51 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/53 | 0/51 |
| Wrist fractureInjury, poisoning and procedural complications | 1/53 | 0/51 |
| Event | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) |
|---|---|---|
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 48/53 | 45/51 |
| Fatigue (FATIGUE)General disorders | 31/53 | 27/51 |
| Headache (HEADACHE)Nervous system disorders | 25/53 | 21/51 |
| Swelling (SWELLING)General disorders | 17/53 | 7/51 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 16/53 | 14/51 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 14/53 | 6/51 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 14/53 | 13/51 |
| Chills (CHILLS)General disorders | 11/53 | 11/51 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 8/53 | 7/51 |
| COVID-19Infections and infestations | 5/53 | 0/51 |
For B1971060: all enrolled participants who received at least 1 dose of the study Intervention. For B1971057: Historical data of the age- and sex-matched healthy participants (selected randomly) as reference for current study.
| Age, Customized(Participants) | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) | Total |
|---|---|---|---|
| 2-11 years | 2 | 2 | 4 |
| 12-17 years | 8 | 6 | 14 |
| 18-64 years | 40 | 43 | 83 |
| 65-84 years | 3 | 0 | 3 |
| Sex: Female, Male(Participants) | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) | Total |
|---|---|---|---|
| Female | 23 | 21 | 44 |
| Male | 30 | 30 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 7 | 7 |
| Not Hispanic or Latino | 53 | 44 | 97 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Trumenba (B1971060) | Trumenba (B1971057, Historical Age- and Sex-Matched Control) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 3 | 3 |
| White | 53 | 46 | 99 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2021 to primary completion in Sep 2023, 24 months.
Results were first posted in Oct 2024, 1 year 1 month after primary completion.
Of 20 phase 4 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 41. This study's 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine